Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide plus ADT in high-risk localized or locally advanced prostate cancer undergoing radical prostatectomy
CTR20192042Phase 3Terminated
- Sponsor
- Aragon Pharmaceuticals
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apalutamide in prostate cancer (PCa), sponsored by Aragon Pharmaceuticals. Started Oct 2019; status: terminated.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20192042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192042.